Xenetic’s Lead Drug Candidate ErepoXen Shows Encouraging Results In CKD Clinical Study
News
Results from a clinical trial of ErepoXen — a therapy developed by Xenetic Biosciences to treat anemia in chronic kidney disease (CKD) patients, show promise, company officials said in a review of their proprietary ... Read more